WO2002074941A8 - Reportervirus mit heterologen hüllproteinen - Google Patents

Reportervirus mit heterologen hüllproteinen

Info

Publication number
WO2002074941A8
WO2002074941A8 PCT/EP2002/003185 EP0203185W WO02074941A8 WO 2002074941 A8 WO2002074941 A8 WO 2002074941A8 EP 0203185 W EP0203185 W EP 0203185W WO 02074941 A8 WO02074941 A8 WO 02074941A8
Authority
WO
WIPO (PCT)
Prior art keywords
envelope proteins
reporter virus
virus
reporter
heterologous envelope
Prior art date
Application number
PCT/EP2002/003185
Other languages
English (en)
French (fr)
Other versions
WO2002074941A1 (de
Inventor
Frank Kirchhoff
Jan Muench
Original Assignee
Ipf Pharmaceuticals Gmbh
Frank Kirchhoff
Jan Muench
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipf Pharmaceuticals Gmbh, Frank Kirchhoff, Jan Muench filed Critical Ipf Pharmaceuticals Gmbh
Priority to AU2002310969A priority Critical patent/AU2002310969A1/en
Publication of WO2002074941A1 publication Critical patent/WO2002074941A1/de
Publication of WO2002074941A8 publication Critical patent/WO2002074941A8/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15061—Methods of inactivation or attenuation
    • C12N2740/15062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Gegenstand der Erfindung ist ein Reportervirus auf der Basis von Lentiviren, Rhabdoviren oder Foamyviren. Das Reportervirus ist mit Hüllproteinen aus Viren aus den Familien der Flaviviren, insbesondere Hepatitis C-Virus, Paramyxoviren, Orthomyxoviren, Arenaviren und Hepadnaviren, Fragmenten dieser Hüllproteine oder Fusionsproteinen dieser Hüllproteine pseudotypisiert und enthält ein Reportergen. Die Erfindung betrifft auch Verfahren zum Auffinden von Substanzen mit Wirksamkeit gegen virale Infektionen und Verfahren zur Herstellung des Reportervirus.
PCT/EP2002/003185 2001-03-21 2002-03-21 Reportervirus mit heterologen hüllproteinen WO2002074941A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002310969A AU2002310969A1 (en) 2001-03-21 2002-03-21 Reporter virus comprising heterologous envelope proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10113864.4 2001-03-21
DE10113864 2001-03-21

Publications (2)

Publication Number Publication Date
WO2002074941A1 WO2002074941A1 (de) 2002-09-26
WO2002074941A8 true WO2002074941A8 (de) 2002-10-24

Family

ID=7678450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/003185 WO2002074941A1 (de) 2001-03-21 2002-03-21 Reportervirus mit heterologen hüllproteinen

Country Status (2)

Country Link
AU (1) AU2002310969A1 (de)
WO (1) WO2002074941A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454989A1 (de) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infektiöse HCV Pseudo-Partikel, welche native funktionelle E1 und E2 Proteine beinhalten
ATE430798T1 (de) 2002-09-13 2009-05-15 Inst Nat Sante Rech Med Infektiöse hepacivirus-pseudopartikel mit funktionellen e1-, e2-hüllproteinen
EP1398371A1 (de) * 2002-09-13 2004-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infektiöse HCV Pseudopartikel mit funktionellen E1 and E2 Hüllproteinen
EP1454988A1 (de) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infektiöse Flavivirus Pseudo-Partikel, welche funktionelle prM-E Hüllproteine enthalten
WO2005047481A2 (en) 2003-11-12 2005-05-26 Progenics Pharmaceuticals, Inc. Novel sequences encoding hapatitis c virus glycoproteins
WO2007029857A1 (ja) * 2005-09-09 2007-03-15 National University Corporation Gunma University B型肝炎ウイルスの感染性の測定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4096100A (en) * 1999-04-23 2000-11-10 Centre For Translational Research In Cancer Pseudotyped retroviral vector for gene therapy of cancer

Also Published As

Publication number Publication date
AU2002310969A1 (en) 2002-10-03
WO2002074941A1 (de) 2002-09-26

Similar Documents

Publication Publication Date Title
WO2003054197A3 (de) A librairy of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
HK1152084A1 (en) Method of preventing virus:cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins
NO20056074L (no) Hoy titer rekombinante influensavira til vaksiner og genterapi
WO2002000885A3 (en) Assembly of wild-type and chimeric influenza virus-like particles (vlps)
WO2004042001A3 (en) Virus-like particles, methods of preparation, and immonogenic compositions
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
ATE437222T1 (de) Alphavirus replikon-vektorsysteme
WO2006136448A3 (en) Attenuated sars and use as a vaccine
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
WO2002074941A8 (de) Reportervirus mit heterologen hüllproteinen
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2005035712A3 (en) Methods and compositions for infectious cdna of sars coronavirus
WO2003072725A3 (en) Recombinant negative strand virus rna expression systems and vaccines
AU2002225509A1 (en) Production and of viruses, viral isolates and vaccines
WO2003053332A3 (en) Composition and method for treating viral infection
WO2002042450A8 (en) Sugarcane bacilliform virus promoters derived from isolates isolated from sugarcane cultivars
WO2003029274A3 (en) Paramyxoviruses as gene transfer vectors to lung cells
WO2022063986A3 (en) Synthetic viruses
WO2003016521A3 (de) Aav-vektor-verpackungsplasmide zur helfervirus-freien herstellung von wtaav-partikeln oder pseudotypisierten aav-partikeln über einzeltransfektion
WO2004104032A3 (en) Methods and compositions related to high-titer pseudotyped retroviruses
WO2004048403A3 (en) Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
WO2003057824A3 (en) Compositions and methods for the inhibition of membrane fusion by paramyxoviruses
ATE489106T1 (de) Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
WO2002096940A3 (en) Attenuated very virulent infectious bursal disease virus
EP0972523A3 (de) Methode und Zusammensetzungen zur Induktion einer Antivirusimmunität

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 39/2002 UNDER (51) REPLACE THE EXISTING SYMBOLS BY "C12N 7/01, C12Q 1/70"

Free format text: PAT. BUL. 39/2002 UNDER (51) REPLACE THE EXISTING SYMBOLS BY "C12N 7/01, C12Q 1/70"

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP